The FDA granted accelerated approval to sibeprenlimab injection (Voyxact) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk for disease progression, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results